doi: 10.1161/01.RES.0000256354.95791.f1
© 2007 American Heart Association, Inc.
Reviews |
Overview of PDEs and Their Regulation
From the Discovery Research Laboratories, Tanabe Seiyaku Co Ltd, Saitama, Japan.
Correspondence to Kenji Omori, Discovery Research Laboratories, Tanabe Seiyaku Co Ltd, 2-50 Kawagishi 2-chome, Toda, Saitama 335-8505, Japan. E-mail k-omori{at}tanabe.co.jp
This Review is part of a thematic series on Phosphodiesterases, which includes the following articles:
Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic
Nucleotide Phosphodiesterases
Overview of PDEs and Their Regulation
Regulation of Phosphodiesterase 3 (PDE3) and Inducible cAMP Early Repressor (ICER) in the Heart
cAMP and cGMP Signaling Cross-Talk: Role of Phosphodiesterases and Implications for Cardiac Pathophysiology
cAMP Specific Phosphodiesterase-4 Enzymes in the Cardiovascular System: A
Molecular Toolbox for Generating Compartmentalized cAMP Signalling PDE5
David A. Kass Editor
 |
Abstract |
|---|
 Top Abstract IntroductionPDE FamilyGeneral CharacteristicsPDE Variants and Their...Gene Regulation in PDEsEnzymatic Regulation of PDEs...Subcellular Localization of...Phenotypes of Genetically...ConclusionsReferences |
|---|
Contraction and relaxation of vascular smooth muscle and cardiac myocytes are key physiological events in the cardiovascular system. These events are regulated by second messengers, cAMP and cGMP, in response to extracellular stimulants. The strength of signal transduction is controlled by intracellular cyclic nucleotide concentrations, which are determined by a balance in production and degradation of cAMP and cGMP. Degradation of cyclic nucleotides is catalyzed by 3',5'-cyclic nucleotide phosphodiesterases (PDEs), and therefore regulation of PDEs hydrolytic activity is important for modulation of cellular functions. Mammalian PDEs are composed of 21 genes and are categorized into 11 families based on sequence homology, enzymatic properties, and sensitivity to inhibitors. PDE families contain many splice variants that mostly are unique in tissue-expression patterns, gene regulation, enzymatic regulation by phosphorylation and regulatory proteins, subcellular localization, and interaction with association proteins. Each unique variant is closely related to the regulation of a specific cellular signaling. Thus, multiple PDEs function as a particular modulator of each cardiovascular function and regulate physiological homeostasis.
Key Words: cAMP • cGMP • cyclic nucleotide • cell signaling • phosphodiesterase inhibitor
|
Introduction |
|---|
|
TopAbstractIntroductionPDE FamilyGeneral CharacteristicsPDE Variants and Their...Gene Regulation in PDEsEnzymatic Regulation of PDEs...Subcellular Localization of...Phenotypes of Genetically...ConclusionsReferences |
|---|
Numerous cellular functions are regulated by second messengers, cAMP and cGMP (Figure 1). In the cardiovascular system, blood pressure is regulated by contraction and relaxation of vascular smooth muscle in association with vascular endothelial functions. Beating of cardiac myocytes is accurately controlled to pump blood out of the heart to other parts of the body according to environmental conditions. These events in hemodynamics are ingeniously regulated by extracellular stimulation through alteration of intracellular cyclic nucleotide levels, which are determined by a balance between their production and degradation by 3',5'-cyclic nucleotide phosphodiesterases (PDEs).1–5 Downstream effector proteins of cAMP and cGMP are cAMP-dependent protein kinase (PKA), cGMP-dependent protein kinase (PKG), cyclic nucleotide-gated ion channels, and cAMP-regulated guanine nucleotide exchange factors (cAMP-GEFs), which are also called exchange proteins directly activated by cAMP (Epacs). PDEs are also downstream effectors of cAMP and cGMP. Recent studies on cyclic nucleotide–mediated signaling have revealed that the signal for each physiological event is independently regulated by compartmentation of certain signaling molecules.6 PDEs are closely related to the regulation of each specific transduction signal, and therefore multiple PDEs play important roles in modulating each cellular function. Our goal here is to give an overview of the expanding molecular characteristics of PDE families principally in humans.
|
|
PDE Family |
|---|
|
TopAbstractIntroductionPDE FamilyGeneral CharacteristicsPDE Variants and Their...Gene Regulation in PDEsEnzymatic Regulation of PDEs...Subcellular Localization of...Phenotypes of Genetically...ConclusionsReferences |
|---|
PDEs are classified into classes I, II, and III. Mammalian PDEs, which belong to class I PDEs, have an HD domain (Pfam accession no. PF01966) in the C-terminal half and show high affinity for cAMP and/or cGMP. Protein domains involved in regulation of PDE enzymatic activity and subcellular localization are mainly present in the N-terminal half. Some PDEs have phosphorylation sites targeted by protein kinases and lipid modification sites (Figure 2).
|
Twenty-one class I PDE genes have been identified in human, rat, and mouse (Figure 3). They are categorized into 11 different families based on structural similarity such as sequence homology, protein domains, and enzymatic properties, including substrate specificity, kinetic properties, and sensitivity to endogenous regulators and inhibitors (Table 1 and the online supplemental Table, available at http://circres.ahajournals.org). Approximately 270 aa in the C-terminal catalytic domain are conserved, with a sequence identity of 35% to 50% among different PDE families. Some PDE families are composed of 2 to 4 subfamily genes showing sequence identity of more than 70% and having identical protein domains organization. Multiple transcriptional products, which are generated from most PDE genes by alternative splicing or transcription from distinct promoters, have actually been identified or predicted in human DNA databases. Thus, the mammalian PDE superfamily is composed of 21 genes and their multiple transcriptional splice variants.
|
|
According to the nomenclature used for each PDE isozyme (eg, HsPDE1A1), the first 2 letters indicate the animal species and the first Arabic number after PDE designates the PDE gene family. This number is followed by a single capital letter indicating a distinct subfamily gene. The last Arabic number indicates a specific splice variant or a specific transcript generated from a unique transcription initiation site (http://depts.washington.edu/pde/pde.html).
The unique characteristics of each PDE gene family are defined by protein domains located in the N terminal to the catalytic unit. As shown in Figure 2, approximately half of PDE gene families (PDE2, PDE5, PDE6, PDE10, and PDE11) have a protein domain termed GAF [Pfam accession no. PF01590] in tandem and are therefore designated GAF-PDE subfamily. The known functions of GAF domains are cGMP binding-mediated allosteric regulation and dimerization of GAF-PDEs. Some GAF domains have also been reported to bind cAMP. Other PDEs (PDE1, PDE3, PDE4, and PDE7–9) have no GAF domain and belong to the non–GAF-PDE subfamily. PDE1 contains a Ca2+/calmodulin (CaM)-binding site, PDE3 has a transmembrane domain, PDE4 has upstream conserved regions (UCRs), and PDE8 has a response regulator receiver (REC) domain [Response_reg; Pfam accession no. PF00072] and a per–arnt–sim (PAS) domain [Pfam accession no. PF00989]. PDE7 and PDE9 have no specific protein domain in addition to the PDE catalytic domain.
|
General Characteristics |
|---|
|
TopAbstractIntroductionPDE FamilyGeneral CharacteristicsPDE Variants and Their...Gene Regulation in PDEsEnzymatic Regulation of PDEs...Subcellular Localization of...Phenotypes of Genetically...ConclusionsReferences |
|---|
Fundamental information about the 11 human PDE gene families and PDE inhibitors are summarized in Table 1 and the online supplemental Table.
Phosphodiesterase 1
Three subfamily genes, PDE1A to -C, encode Ca2+/CaM-dependent cAMP- and cGMP-hydrolyzing PDEs. In humans, PDE1A shows high affinity for cGMP.8 PDE1B hydrolyzes cGMP with a Km value lower and a Vmax value higher than those for cAMP.9 High affinity for both cAMP and cGMP is observed with PDE1C.8
Phosphodiesterase 2
PDE2A hydrolyzes both cGMP and cAMP with similar maximal rates and relatively high Km values. PDE2A is allosterically stimulated by cGMP binding to its GAF domain,10 which enables mutual regulation of both cAMP and cGMP signaling.
Phosphodiesterase 3
PDE3A and PDE3B are the subfamily genes of PDE3, which shows high affinity for both cAMP and cGMP. A low Vmax value for cGMP compared with that for cAMP lets cGMP function as a competitive inhibitor for cAMP hydrolysis.2 Therefore, PDE3s are termed cGMP-inhibited cAMP PDEs. The presence of a 44-aa insert in the catalytic domain is a unique characteristic of the PDE3 family. Another special feature is the presence of N-terminal hydrophobic membrane association domains (NHRs).11
Phosphodiesterase 4
Four highly similar subfamily genes, PDE4A to -D, encode cAMP-specific rolipram-sensitive PDEs. The PDE4 family includes a number of splice variants categorized into 3 N-terminal variant groups ("long form," "short form," and "super-short form"12) based on the presence or absence of N-terminal UCR domains (Figure 2).13 The long form variants contain UCR1, linker region (LR) 1, UCR2, LR2, and the catalytic domain. The short form and the super-short form variants have LR1-UCR2-LR2 and UCR2 (truncated)-LR2 in the N-terminal region, respectively. UCR1, which includes 1 PKA phosphorylation site, is connected to UCR2 by LR1. UCR2 has a hydrophilic N-terminal region, which intramolecularly interacts with the hydrophobic C-terminal portion of UCR1.14 UCR1 and UCR2 are involved in PDE4 enzymatic regulation15–17 through UCR2 interaction with the catalytic domain18 and have also been reported to participate in PDE4 dimerization.19 Although PDE4 catalytic site binds to the competitive inhibitor rolipram, the affinity of this site for rolipram can change markedly depending on the conformation of the enzyme. This can result in the so-called high-affinity rolipram-binding site, HARBS.
Phosphodiesterase 5
PDE5A, which has 2 GAF domains (GAF A and GAF B) in the N-terminal half, specifically hydrolyzes cGMP. PDE5A GAF A domain has been reported to be responsible for this enzyme allosteric binding to cGMP,20 and therefore PDE5A is termed cGMP-binding cGMP-specific PDE. One PKG- and PKA-dependent phosphorylation site in the N-terminal region is related to activation of PDE5A enzyme.21 cGMP binding to PDE5A GAF A domain promotes phosphorylation, which not only activates the catalytic function but also increases cGMP-binding affinity.21–23
Phosphodiesterase 6
In retinal rod and cone cells, the level of cGMP, a second messenger in visual signal transduction, is tightly controlled through regulated cGMP hydrolysis by 3 PDE6 subfamily genes (photoreceptor PDEs).5 Light-activated transducin stimulates PDE6 activity by removing the inhibitory subunit 
. Membrane hyperpolarization is caused by cGMP elimination, leading to electrical cellular response. PDE6
and PDE6ß subunits encoded by the PDE6A and PDE6B genes, respectively, form a holoenzyme, rod PDE, with 2 copies of the smaller inhibitory subunit (PDE6) encoded by PDE6G. GAF A domain is related to PDE6ß heterodimerization.24 In cone cells, a homodimer of 2 ' subunits (PDE6') encoded by PDE6C comprises cone PDE with cone-specific inhibitory subunits encoded by PDE6H. Thus, regulation of PDE6 activity by small inhibitory subunits is a unique aspect of this PDE family. Sildenafil, vardenafil, and udenafil, but not tadalafil, inhibit PDE6 with substantially lower affinities than those for PDE5A.
Phosphodiesterase 7
Two subfamily genes, PDE7A and PDE7B, encode rolipram-insensitive high-affinity cAMP-specific PDEs (Km value, approximately 0.2 µmol/L25). A PKA pseudosubstrate site is present in the N terminus of PDE7A subfamily.26 Dipyridamole nonselectively inhibits PDE7 activity.
Phosphodiesterase 8
PDE8A and PDE8B are the subfamily genes of PDE8. PDE8s are high-affinity cAMP-specific PDEs insensitive to rolipram and 3-isobutyl-1-methylxanthine (IBMX),27 and contain REC and PAS domains in the N-terminal portion. REC domain functions as a receiver of signals from the sensor component in 2-component signal transduction system in lower organisms. PAS domain is involved in the binding of small ligands and protein–protein interaction. However, regulation of PDE8s via REC or PAS domain is unknown, and obvious endogenous PDE8 activity has not yet been demonstrated in either tissue or cell extracts. Actually, many studies on IBMX-insensitive cAMP PDE activity have been reported. It is true that this activity has, for the most part, not been definitively ascribed to PDE8, but it is very likely attributable to PDE8. Dipyridamole inhibits PDE8 activity but not selectively.
Phosphodiesterase 9
PDE9A specifically hydrolyzes cGMP with high affinity.28,29 However, there is no report on the regulation of PDE9A activity or the presence of endogenous PDE9A activity in either tissue or cell extracts. IBMX-insensitive cGMP PDE activity, which has been shown so far, is likely attributable to PDE9.
Phosphodiesterase 10
PDE10A contains 2 N-terminal GAF domains and hydrolyzes both cAMP and cGMP.30 High affinity for cAMP inhibits cGMP hydrolysis, making this enzyme a cAMP-inhibited dual-substrate PDE. Among newly discovered PDEs, the enzymatic activity of PDE10A is clearly demonstrated in tissue extracts.31 The enzymatic activity of a chimeric construct of PDE10A GAF domain and cyanobacterial adenylyl cyclase is stimulated by cAMP, suggesting a possible allosteric modulation of PDE10A activity by cAMP.32 Papaverine is known as the most potent inhibitor of PDE10A.33
Phosphodiesterase 11
A full-length form, PDE11A4, contains 2 GAF domains and a catalytic domain. PDE11A hydrolyzes both cAMP and cGMP with similar Km values.34–36 Although a cyanobacterial adenylyl cyclase fused with PDE11A4 GAF domains is activated by cGMP,32 there is no report on the allosteric regulation of PDE11A enzyme. PDE11A activity has not yet been clearly demonstrated in tissue or cell extracts. Tadalafil has been shown to potently inhibit PDE11A activity still much less potently than it inhibits PDE5A.
|
PDE Variants and Their Tissue-Expression Patterns |
|---|
|
TopAbstractIntroductionPDE FamilyGeneral CharacteristicsPDE Variants and Their...Gene Regulation in PDEsEnzymatic Regulation of PDEs...Subcellular Localization of...Phenotypes of Genetically...ConclusionsReferences |
|---|
Phosphodiesterase 1
N-terminal and C-terminal variants of PDE1A are divided into 3 groups based on their N-terminal sequences (Figure 2). In humans, PDE1A5 (PDE1A2), PDE1A6 (PDE1A3), and PDE1A9 encode the N-terminal sequence N1, whereas PDE1A1, PDE1A4, and PDE1A8 have the N-terminal sequence N2. The N-terminal sequence N3 is encoded by PDE1A10 to -1A12.37 These N-terminal sequences differ in Ca2+/CaM-binding domain, and therefore activation by Ca2+/CaM is N-terminal sequence dependent. PDE1As carrying the N2 sequence are activated by Ca2+/CaM, whereas activation of PDE1As with the N1 sequence is not statistically significant.38 There is no report on the activation of PDE1As with the N3 sequence. In humans, PDE1A5 and PDE1A6 expression is brain specific, whereas PDE1A1 and PDE1A4 expression is ubiquitous but high in the kidney, liver, pancreas, and thyroid gland.37,39 PDE1A10 expression is testis specific.37 In mice, expression of the 61-kDa PDE1 protein (PDE1A) has been reported in the brain.40
There are 2 N-terminal variants in humans, PDE1B1 and PDE1B2. PDE1B1 expression is predominant in the caudate nucleus and putamen of the brain39 and low in the heart and skeletal muscle.41 PDE1B2 transcripts are found mostly in the spinal cord.39 Detailed expression of the 63-kDa PDE1 protein (PDE1B) has been reported in mouse brain.40
PDE1C1 and PDE1C3 are human N-terminal variants. Rat PDE1C2 encodes distinct N- and C-terminal sequences. PDE1C4 and PDE1C5, both of which encode the same 654-aa protein, are C-terminal variants of PDE1C1 in mice.42 Human PDE1C expression is high in the heart and brain.8 Rat PDE1C transcripts are very few in the heart but are abundant in olfactory epithelium.44 Mouse PDE1C1 and PDE1C5 transcripts are very few in the heart but are abundant in the cerebellum.42
Phosphodiesterase 2
The PDE2A gene encodes 3 N-terminal splice variants containing 2 GAF domains. PDE2A3, which is a human variant, is membrane associated probably because of its unique N-terminal sequence.45 PDE2A3 transcripts are rich in the brain and moderate in the heart. Immunoreactive PDE2A protein is rich in the neocortex and low in other tissues, and its signals are also localized in capillary and venous endothelial cells and in microvessel endothelial cells but not in arterial endothelial cells of intact tissues.46 In contrast, cultured endothelial cells exhibit PDE2 activity.47
Phosphodiesterase 3
Transcripts of PDE3A1 (8.2 kb) and PDE3A2 (6.9 kb) carrying distinct 5' regions are produced by alternative transcription within exon 1 in human cardiovascular system.11,48 These 2 transcripts encode 3 N-terminal variant forms, PDE3A-136 (136 kDa), PDE3A-118 (118 kDa), and PDE3A-94 (94 kDa) (Figure 2). PDE3A1 encodes PDE3A-136, which includes 2 N-terminal hydrophobic membrane association domains (NHR1 and NHR2) and the catalytic domain. PDE3A2 encodes PDE3A-118 (NHR2 to the catalytic domain) and PDE3A-94 (the catalytic domain), which are translated from alternative translation initiation sites.11 In human placenta, the 4.4-kb transcript PDE3A3, which is generated from exon 4, encodes PDE3A-94.49 Only PDE3A-136 has the Akt/protein kinase B (PKB) phosphorylation site, which is critical for enzymatic activation. PKA phosphorylation site is present in PDE3A-136 and PDE3A-118, but not in PDE3A-94. PDE3A1 expression is low in cardiac myocytes, but PDE3A2 expression is high in both cardiac and vascular myocytes.11 PDE3A expression is observed in heart, vascular and placental smooth muscle, corpus cavernosum smooth muscle, and platelets.2 Rat PDE3A transcripts are abundant in the myocardium, smooth muscle, epithelium, megakaryocytes, and oocytes.50
Conversely, only PDE3B1 has been identified in humans. PDE3B transcripts are predominant in human adipose tissue.51 In rats, PDE3B expression is evident in white and brown adipose tissues and is also found in hepatocytes, renal collecting duct epithelium, and developing spermatocytes. PDE3B transcripts are also abundant in embryonic neuroepithelium including neural retina but not in mature nervous system.50
Phosphodiesterase 4
PDE4A1 encodes a short form protein. Long forms of PDE4A proteins are encoded by PDE4A4B, PDE4A8, PDE4A10, and PDE4A11. In humans, PDE4A expression is fundamentally ubiquitous52,53 and relatively high in the brain13 with variant-specific tissue distribution pattern. PDE4A4B transcripts are found in T cells,52 and PDE4A10 expression is high in the heart and small intestine.54 PDE4A11 transcripts are widely observed in various tissues55 with high expression in fetal brain but not in adult brain.54 In rats, PDE4A transcripts are rich in brain neurons and the olfactory system.56
The long forms PDE4B1 and PDE4B3 and the short form PDE4B2 are human PDE4B variants. PDE4B4, which encodes a long form protein, is an additional variant in rats.57 PDE4B are widely distributed in various tissues with variant-specific tissue distribution pattern. In immune cells, PDE4B and PDE4D isoforms are predominant compared with PDE4A and PDE4C isoforms. Human PDE4B2 transcripts are abundant in leukocytes, especially neutrophils.58 Transcripts of PDE4B2, which is the major PDE4B isoform in normal B cells, are abundant in naive and memory B cells and low in centroblasts and centrocytes.59 In rats, PDE4B3 transcripts are present in the brain, heart, lung, and liver, whereas PDE4B4 expression is specific to the liver and brain.57
The long forms PDE4C1, PDE4C2, and PDE4C3, which are generated from distinct promoters, have been identified in humans. PDE4C-
54 and PDE4C-109 transcription is thought to be driven from a separated common promoter. PDE4C-791 is the 5' alternate of PDE4C1 but is predicted to encode the same protein. PDE4C expression is ubiquitous but has been reported to be low in the lung and absent in blood.53 PDE4C-54 expression is testis specific. In general, expression of PDE4C variants is not fully understood.
In humans, PDE4D3 to -4D5 and PDE4D7 to -4D9 encode long forms, and PDE4D1 encodes a short form. Super-short forms are encoded by PDE4D2 and PDE4D6. In general, like PDE4B, PDE4D expression predominates in various tissues. However, PDE4D4 and PDE4D6 expression is brain specific, and PDE4D7 transcripts are ubiquitously distributed but are abundant in the lung and kidney. PDE4D8 transcripts are rich in the heart and skeletal muscle, suggesting muscle-specific expression.61–63 PDE4D5 enzyme is the most dominant in well-differentiated human bronchial epithelium (WD-HBE) cells.64 In rats, PDE4D1 to -4D3, PDE4D5, and PDE4D9 transcripts are broadly distributed in most tissues, whereas PDE4D4 and PDE4D6 to -4D8 show variant-specific tissue expression patterns.65
Phosphodiesterase 5
N-terminal variants PDE5A1 to -5A3, which show similar Km values (eg, 
6 µmol/L) have been identified in humans (Figure 2).66–68 One N-terminal phosphorylation site for PKA and PKG is conserved among all 3 variants. In humans, PDE5A transcripts are rich in various tissues, especially in smooth muscle tissues, and are also detected in platelets.66,67 PDE5A1 and PDE5A2 transcripts are widely distributed.67,68 In contrast, specific expression of PDE5A3 in smooth and/or cardiac muscle has been suggested.68
Phosphodiesterase 6
Splice variants of PDE6A to -6C have not been reported. PDE6A and PDE6B transcripts are present in rod cells, whereas PDE6C transcripts are in cone cells.5
Phosphodiesterase 7
Three variant forms have been reported in human PDE7A subfamily. PDE7A1 and PDE7A2 are N-terminal variants,26 and PDE7A3 is a C-terminal variant of PDE7A1.69 PDE7A1 expression is ubiquitous, whereas PDE7A2 transcripts are confined to the heart, skeletal muscle, and kidney. PDE7A3 expression has been demonstrated in the heart, skeletal muscle, spleen, thymus, testis, and peripheral blood leukocytes.69 In mice, PDE7A expression is highest in the skeletal muscle, followed by the spleen, uterus, heart, brain, and kidney but is insignificant in the testis.70
Only PDE7B1 has been identified in humans and mice. In rats, there are 3 N-terminal splice variants, PDE7B1 to -7B3. Human PDE7B transcripts are observed in the caudate nucleus and putamen of the brain, heart, and several other tissues.71 In rats, PDE7B expression is particularly high in the testis and neuronal cells of several brain regions72,73 and is also detected in the heart, lung, skeletal muscle, and kidney.72 In mice, PDE7B transcripts are rich in the pancreas and can also be found in the brain, heart, thyroid, and skeletal muscle.74
Phosphodiesterase 8
In humans, 5 PDE8A splice variants, PDE8A1 to -8A5, have been identified. The longest form, PDE8A1, contains REC and PAS domains. PDE8A transcripts are expressed in various tissues and are abundant in the testis, ovary, small intestine, and colon.75 In general, PDE8A1 expression is dominant as compared with that of other PDE8A variants.76 In rats, PDE8A expression is high in the liver and testis.77
Five splice variants of PDE8B have also been reported in humans. PDE8B1, the longest form, carries REC and PAS domains.27 In humans, PDE8B transcripts are predominant in the thyroid gland and are low in most brain areas except the cerebellum.78 Rat PDE8B transcripts are not confined to the thyroid gland. They are abundant in the brain and are detectable in neuronal cells of several brain regions other than the cerebellum.77
Phosphodiesterase 9A
Although 21 splice variants of PDE9A have been identified in humans,79 differences in functional characteristics and subcellular localization among these variants have not yet been reported in detail. PDE9A1 is the longest form of PDE9A variants. Expression of PDE9A transcripts is high in the spleen, small intestine, brain, colon, prostate, kidney, and placenta.28,29 Transcripts of PDE9A1 and PDE9A6 (described as PDE9A5 in the literature) are predominant in some immune tissues.80
Phosphodiesterase 10
Two major N-terminal variants, PDE10A1 and PDE10A2, and several minor variants have been identified in humans.30,81 A PKA phosphorylation site in PDE10A2 is the most striking difference between PDE10A2 and PDE10A1.82 In most human tissues, PDE10A2 expression is higher than that of PDE10A1.82 PDE10A transcripts are particularly rich in the putamen, caudate nucleus, and testis.30 PDE10A transcripts are present in neurons of the striatum, caudate nucleus, nucleus accumbens, and olfactory tubercles in rat brain.31,83 In mice, PDE10A expression is highest in the testis and brain.84 Histologically, PDE10A expression is high in the striatal medium spiny neurons (MSNs). However, signal intensity among brain areas in mice, rats, dogs, cynomolgus macaques, and humans is different.85
Phosphodiesterase 11
Four N-terminal variants are encoded by PDE11A1 to -11A4 (Figure 2). PDE11A4 encodes the longest protein including 2 GAF domains and 2 N-terminal phosphorylation sites for PKA and PKG.34 PDE11A variants are unique in showing various GAF domain organization.34–36
In humans, PDE11A expression is strong in the prostate and moderate in the testis and several other tissues.34,35 Transcripts of PDE11A1, PDE11A3, and PDE11A4 are mostly confined to the skeletal muscle, testis, and prostate, respectively.86 Among PDE11A variant proteins, only PDE11A4 protein has been clearly detected in human tissues by immunochemical analysis.87 Rat PDE11A4 transcripts are not prostate specific.88
|
Gene Regulation in PDEs |
|---|
|
TopAbstractIntroductionPDE FamilyGeneral CharacteristicsPDE Variants and Their...Gene Regulation in PDEsEnzymatic Regulation of PDEs...Subcellular Localization of...Phenotypes of Genetically...ConclusionsReferences |
|---|
Expression of PDE transcripts has been reported to increase or decrease in various tissues; however, a molecular mechanism of PDE gene regulation has, in many cases, not been clarified in detail. In this section, regulation of PDEs in the cardiovascular and immune systems is highlighted.
Phosphodiesterase 1
Long-term nitrate treatment increases the expression of PDE1A1 transcripts and protein in rat aortas, which leads to nitrate tolerance.89 PDE1B is known as an early response gene.90 Granulocyte macrophage colony–stimulating factor upregulates PDE1B2 expression in differentiating monocytes.91 PDE1C expression is observed in proliferative phenotypes of human arterial smooth muscle cells (SMCs) but not in quiescent SMCs.92 Treatment with a stable prostacyclin derivative, 7-oxo-prostacyclin, upregulates PDE1C expression in rat heart.93
Phosphodiesterase 2
PDE2A expression is induced by macrophage colony–stimulating factor in human monocytes differentiating into peritoneal macrophage.91 Epinephrine infusion has been reported to stimulate skeletal muscle PDE2A expression in young men.94 Tumor necrosis factor (TNF) increases the levels of PDE2A3 transcripts in human umbilical vein endothelial cells (HUVECs) via p38 mitogen-activated protein kinase activation, which might lead to destabilization of endothelial barrier function.95
Phosphodiesterase 3
Reduction in PDE3A expression has been reported in human failing hearts.96 Angiotensin II and isoproterenol induce sustained downregulation of PDE3A expression and upregulation of inducible cAMP early repressor (ICER) expression in cardiac myocytes.96 ICER induction represses PDE3A expression, leading to activation of cAMP/PKA signaling, which contributes to ICER expression. Sustained ICER induction leads to cardiomyocyte apoptosis. This is a unique autoregulatory positive feedback mechanism denoted as the PDE3A-ICER feedback loop.97
PDE3B expression requires peroxisome proliferator–activated receptor (PPAR)98 and is upregulated during differentiation to adipocytes in 3T3-L1 cells.99 In contrast, treatment of fully differentiated 3T3-L1 adipocytes with TNF reduces PDE3B expression.100 In addition, C2-ceramide (a short-chain ceramide analog), which is involved in TNF signaling, decreases the level of PDE3B protein.101 Troglitazone, an antidiabetic drug, antagonizes ceramide action on PDE3B expression.
Phosphodiesterase 4
Expression of certain PDE4 isoforms is altered by rapid or chronic treatment with cAMP-stimulating agents.102 In human monocytic U937 cells, steady-state mRNA levels of PDE4A and PDE4B are upregulated by cAMP-stimulating agent ß agonist, or rolipram.103 PDE4B expression is potently stimulated in monocytes by lipopolysaccharide via distinct transduction pathways.104 Major PDE4 components, PDE4D3 and PDE4D5, are markedly downregulated during differentiation of monocytic U937 cells to macrophages, whereas PDE4B2 expression is induced.105 Smoking elevates PDE4A4 and PDE4B2 transcription in peripheral blood monocytes, and significant PDE4A4 upregulation is observed in lung macrophages from smokers with chronic obstructive pulmonary disease compared with control smokers.106 In rat heart, treatment with 7-oxo-prostacyclin, a stable prostacyclin derivative, causes upregulation of PDE4B3 transcription and downregulation of PDE4D1/2 and PDE4D3 expressions.93
Rat PDE4D1/2 transcription is driven by a cAMP-responsive promoter, which is TATA-less and contains a number of GC-rich regions, Sp1, AP1, and AP2 sites and GC-rich regions.107 Human PDE4D5 transcription starts from a putative promoter containing a number of CCAAT enhancer-binding protein binding sites (C/EBP) and 2 sites of cAMP response element (CRE).108 Putative promoters for PDE4D6 to -4D8 also contain multiple CRE sites.62 The promoters for human PDE4A10 and PDE4A11 are TATA-less but include GC-rich islands and Sp1 site54,55
Phosphodiesterase 5
Both human PDE5A1 and PDE5A2 promoters are TATA-less and contain putative Sp1 sites in the proximal region.66,67 Lin et al109 report PDE5A1 transcription from a further upstream region (318-bp upstream from the initiation ATG codon) and a core sequence for basal promoter activity. The PDE5A1 promoter is stimulated by cAMP or cGMP through Sp1 sites. The PDE5A2 promoter region, which is situated in an intron between the first exons for PDE5A1 and PDE5A2, is highly GC rich and includes potential Sp1 sites,66,67,110 which are important for basal activity and responsiveness to cAMP and cGMP.110 Lin et al have analyzed PDE5A promoters with COS cells. However, whether these cells are suitable for this type of study is still questionable.
cAMP analogs stimulate transcription of PDE5A, especially PDE5A2 in rat vascular SMCs, whereas cGMP does not.67,111 PDE5A upregulation is unlikely to occur during long-term tadalafil treatment accompanying cGMP stimulation in human corpora cavernosa SMCs.112 No elevation of PDE5A protein, but a slight increase of PDE5A transcripts, has been observed on cGMP stimulation in Tunica albuginea fibroblasts.
Phosphodiesterase 6
The human PDE6A proximal promoter contains 2 indispensable cis elements, a Crx-binding element and an Nrl-response element (NRE).113 The human PDE6B minimal promoter includes ßAp1/NRE and the GC-rich sequence ß/GC necessary for in vitro interaction with Nrl and Sp1/Sp4 (especially Sp4) DNA-binding proteins, respectively.114 The molecular mechanism of PDE6C expression is currently unknown.
Phosphodiesterase 7
The proximal promoter region for human PDE7A1 and likely for PDE7A3 carries no typical TATA motif but contains a CpG island including 3 potential CRE sites.115 In Jurkat T cells, overexpression of CRE binding protein (CREB) increases the promoter activity. In human CD4+ T cells, T-cell activation quickly induces PDE7A1 transcription, whereas PDE7A3 induction is slow.69 PDE7A1 expression is increased in response to intracellular cAMP levels in B lymphocytes.116 Phorbol myristate acetate stimulates the promoter activity, but the molecular mechanism of this stimulation is still unknown.
Expression of rat PDE7B is stimulated by cAMP stimulants in cultured striatal neurons via cAMP-dependent binding of CREB to CRE site in the putative PDE7B1 promoter region.117
Phosphodiesterase 8
Transcription of PDE8A1 is upregulated and reaches a maximum 8 hours after activation of human CD4+ T cells.69
Phosphodiesterase 9 to 11
Regulation of the PDE9A, PDE10A, and PDE11A genes is unknown. Transcription of 2 major PDE10A variants, PDE10A1 and PDE10A2, start from the common promoter, which is highly GC rich and has neither a TATA motif nor a CAAT box.81 The putative promoters for PDE11A1 and PDE11A3 contain a TATA motif. PDE11A4 promoter lacks the TATA motif but includes a GC-rich region, with a CCAAT box and Sp1 site.86
|
Enzymatic Regulation of PDEs by Phosphorylation and Association Proteins |
|---|
|
TopAbstractIntroductionPDE FamilyGeneral CharacteristicsPDE Variants and Their...Gene Regulation in PDEsEnzymatic Regulation of PDEs...Subcellular Localization of...Phenotypes of Genetically...ConclusionsReferences |
|---|
Regulators of PDEs such as kinases and association proteins are listed in Table 2 and illustrated in Figure 4.
|
|
Ca2+/CaM binding to the N-terminal binding site of PDE1s causes marked stimulation of PDE activity. The binding affinities of PDE1A and PDE1B are reduced by PKA- and CaM kinase II–dependent phosphorylation, respectively.118,119 PKA activation has been reported to reduce PDE1C activity in AtT20 cells.120
PDE2A activation by Ca2+/phospholipid-dependent protein kinase has been reported in the liver Golgi–endosomal fraction; however, there is no direct evidence for PDE2A phosphorylation.121 Phosphorylation of rat PDE2A2 by its associated protein kinase inhibits PDE activity.122 However, the molecular basis and enzymatic alteration by PDE2 phosphorylation have not yet been investigated in detail.
Activation of PDE3s by PKA- and PKB-mediated phosphorylation has already been discussed (Figure 2).2 PKA-mediated PDE3A activation functions as negative-feedback regulation in cAMP signaling, and PKB-mediated PDE3B activation in adipocytes greatly contributes to insulin action. However, reported phosphorylation sites of PDE3s are puzzling. In humans, PDE3A is phosphorylated at SHRRTS312 by PKA.123 Human PDE3A contains a site, KXRXXS292, that is similar but not identical to the typical PKB phosphorylation motif RXRXXS. Although PKB phosphorylation of this site is intriguing, detailed analysis of human PDE3A phosphorylation has not been reported. Little is known about PKA- and PKB-mediated phosphorylation of rat PDE3A, which has potential phosphorylation sites.
With regard to PDE3B, human PDE3B contains typical PKB (Ser295) and PKA phosphorylation motifs. However, there is no report on the phosphorylation of these sites. In rat adipocytes, phosphorylation of PDE3B at MFRRPS302 by PKA and/or PKB124 and at QLRRSS427 (Ser442 in humans) by PKA125 has been reported. Mouse PDE3B is phosphorylated by insulin-stimulated PKB at RPRRRS273 (Ser295 in humans, Ser279 in rats), MFRRPS296 (Ser318 in humans, Ser302 in rats), and QLRRSS421 (Ser442 in humans).126,127 Ser273 in mouse PDE3B is situated in a typical PKB phosphorylation site, but the other 2 sites, "RRXS," are fundamentally consensus PKA phosphorylation sites. In addition to PKA and PKB phosphorylation, human PDE3A enzyme is phosphorylated by PKC.123
PDE4 activity is regulated by phosphorylation in UCR1 by PKA and in the C-terminal region by extracellular signal-regulated kinase (ERK), but the regulation is isoform dependent.3,15,16 PKA phosphorylation of the long forms PDE4A4 and PDE4D3 causes their activation probably through disruption of UCR1-UCR2 interaction and UCR2 association with the catalytic region.18,19,128,129 ERK phosphorylates a consensus motif, RXSP, in cooperation with a kinase interaction motif (KIM) situated within the catalytic domains of PDE4B, PDE4C, and PDE4D.16 ERK phosphorylation of the long form PDE4D3 reduces cAMP-hydrolytic activity (ca. 50% inhibition), which in turn leads to PKA activation. Consequently, PKA phosphorylates PDE4 long forms, which escapes ERK-mediated inhibition. Conversely, ERK phosphorylation stimulates activity of the short forms PDE4D1 and PDE4B2 but does not affect that of the super-short form, suggesting the involvement of UCRs in this regulation.16,130 Regulation of PDE4 activity by PKA and ERK phosphorylation depends on PDE4 isoforms and ERK regulatory components in the cells.
The long forms of PDE4 enzymes are activated by phosphatidic acid (acidic) and phosphatidylserine (acidic) but not by phosphatidylcholine (neutral). Alterations in the enzymatic properties of PDE4 isoforms by phosphatidic acid and PKA are similar and exclusive.131 Phosphatidic acid is believed to bind to a specific region of UCR1.17
Immunophilin XAP2 specifically binds to PDE4A5, resulting in inhibition of PDE4 activity, elevation of rolipram sensitivity, and reduction of PKA phosphorylation.132 The motif EELD in UCR2 of PDE4A5 and the C-terminal tetratricopeptide repeat (TPR) domain of XAP2 are involved in this interaction. DISC1 (Disrupted In SChizophrenia 1 gene), a key factor for psychiatric illnesses, interacts with UCR2 of PDE4B and inhibits PDE4B activity. Increased cAMP dissociates DISC1 from PDE4B via PKA activation and reverses PDE4B activity.133 Rat PDE4A5 binds more efficiently to SH3 domains of several tyrosyl kinases, especially Lyn and Fyn, through an SH3-binding site within LR2.134 This association with SH3 domains significantly reduces PDE activity and increases sensitivity to rolipram.135
There are several reports on the regulation of PDE5 by phosphorylation. PDE5 activity is increased by PKA/PKG phosphorylation at Ser102 of human PDE5A1 in vitro.21 Although copurification of PDE6 (P) with PDE5136 has been reported, the physiological significance of this association is unclear, owing to no inhibitory effect of PDE6 on PDE5 activity in vitro.137 In contrast, PDE6ß is inhibited by PDE6 (see section General Characteristics, above). Association of PDE8A1 PAS domain with I
B stimulates PDE8A activity but does not affect nuclear factor B activation.138
Enzymatic regulation of other PDEs is not well understood. The N-terminal sequences of PDE7A, PDE7B, PDE10A2, and PDE11A4 are phosphorylated by PKA in vitro and/or in vivo. However, there is no evidence of enzymatic regulation of these PDEs by phosphorylation. Phosphorylation of PDE8s carrying putative PKA phosphorylation sites has not yet been investigated. There is no report on PDE9A phosphorylation.
|
Subcellular Localization of PDEs, Interaction With Association Proteins, and Compartmentation of Cyclic Nucleotide Signaling |
|---|
|
TopAbstractIntroductionPDE FamilyGeneral CharacteristicsPDE Variants and Their...Gene Regulation in PDEsEnzymatic Regulation of PDEs...Subcellular Localization of...Phenotypes of Genetically...ConclusionsReferences |
|---|
The PKA regulatory subunit binds to the PKA catalytic subunit, and the resultant complex is anchored to particulate fractions. cAMP binding to the regulatory subunit of PKA releases the catalytic subunit for enzymatic activation. A-kinase (PKA) anchoring proteins (AKAPs) play a role in PKA anchoring and function as scaffold molecules for many association proteins.6 Localization of each AKAP is among the important determinants of specific cAMP signaling in cells. With regard to PKG, association of G-kinase (PKG) anchoring proteins (GKAPs) with PKGs has been reported. Membrane anchoring of PKG II is mediated by N-terminal myristoylation. Cyclic nucleotides are generated in limited cellular space where their producer enzymes and/or receptors are located; however, target proteins for cyclic nucleotides are widely distributed. Some PDEs are reported to be localized in microdomains and/or to interact with association proteins including scaffold proteins. Regulation of intracellular PDE localization is recognized as among the key mechanisms in compartmentation of cyclic nucleotide signaling. Association proteins for PDEs are listed in Table 2 and illustrated in Figure 4.
Phosphodiesterase 1
PDE1A protein is predominant in the cytosol of contractile vascular SMCs but is localized in the nucleus of neointimal synthetic vascular SMCs.138 Nuclear PDE1A is involved in regulation of cell proliferation and apoptosis of actively growing synthetic vascular SMCs.139 However, the molecular mechanism of this altered localization is currently unclear. Diffuse cytoplasmic distribution of PDE1B protein has been shown in chick dorsal root ganglion neurons.
Phosphodiesterase 2
Rat PDE2A protein anchors to the membrane with the hydrophobic N-terminal portion140 and is localized at lipid rafts in neurons.141 In cultured neonatal rat ventriculocytes, PDE2A protein is confined to membrane compartment with the sarcomeric Z line. Cyclic nucleotide signaling molecules such as ß-adrenoceptor, adenylyl cyclase, and nitric oxide synthase, are also localized with PDE2A in the lipid rafts, suggesting coupling of these molecules in cardiac signal transduction.142
Phosphodiesterase 3
NHR modules greatly contribute to intracellular localization of PDE3 proteins. PDE3A-136 containing 2 NHRs is exclusively membrane bound. PDE3A-118 carrying NHR2 and PDE3A-94 containing no NHR module are found in both membrane-bound and cytosolic fractions of cardiac and vascular myocytes.11 PDE3A and PDE3B proteins containing 2 NHRs are localized in the endoplasmic reticulum.143 PDE3B protein is associated with caveolae and lipid raft in plasma membrane fractions of adipocytes, suggesting functional importance of this association in insulin signaling.144 A scaffold molecule, 14-3-3ß protein, interacts with rat PDE3B protein phosphorylated via phosphatidylinositol 3-kinase/PKB pathway in adipocytes.127 14-3-3 protein also binds to phosphorylated human PDE3A at Ser428 by PKC.123
Phosphodiesterase 4
PDE4 isoforms show unique intracellular distribution patterns characterized by interaction with several anchoring or targeting proteins such as immunophilin XAP2, DISC1, SH3 domain–containing proteins, ß-arrestin, receptor for activated C-kinase (RACK1), and AKAPs.
ß-Arrestin downregulates ß2-adrenoceptor signaling by inhibiting further interaction with guanine nucleotide binding proteins (G proteins) (Figure 5). Adrenergic stimulation causes time-dependent recruitment of ß-arrestins and PDE4D isoforms to ß2-adrenoceptor at the cell membrane level.145 ß-Arrestin 1 and 2 bind to PDE4 isoforms of all 4 subfamilies through interaction with the C-terminal catalytic domain. PDE4D5 has a distinct ß-arrestin–binding site in the N-terminal region.146 PKA colocalized with AKAP79147 is first activated by cAMP and then phosphorylates the receptor, which causes Gs-to-Gi switch and ERK1/2 activation.148 G protein–coupled receptor kinase recruited to the membrane phosphorylates ß2-adrenoceptor, and then ß-arrestin/PDE4 complex is recruited to the receptor. This PDE4 recruitment contributes to local cAMP degradation, reduction of PKA activity, and modulation of ß2-adrenoceptor function, thus constituting a negative-feedback regulation. Moreover, the recruitment may also regulate ERK signaling.148,149 Regulation of PDE4 by this mechanism is largely dependent on the expression profile of PDE4 isoforms and coexisting PDE4-scaffolding proteins in the cell.
|
Ligation of T-cell Receptor (TCR) with CD28 costimulation causes T-cell activation by cAMP reduction through recruitment of ß-arrestin/PDE4 complex to lipid raft in microdomain. Regulation of compartmentalized cAMP signaling by ß-arrestin/PDE4 complex is considered to be crucial to T-cell regulation.150
RACK1 specifically and directly binds to the N-terminal ß-arrestin–binding site of PDE4D5.147 RACK1-PDE4D5 complex is present in cytosolic fractions. Because the binding of RACK1 and ß-arrestin to PDE4D5 is mutually exclusive, RACK1 might direct cytosolic localization of PDE4D5 by competing with ß-arrestin. RACK1 interaction does not alter PDE4D activity but increases its sensitivity to rolipram.
AKAPs are the most important molecules in compartmentation of cAMP/PDE4 signaling.6 AKAP149 (mitochondria), AKAP95 (perinucleus), and muscle AKAP (mAKAP) (perinucleus151) bind to PDE4A, PDE4A, and PDE4D3, respectively (Table 2). Nuclear membrane anchoring of mAKAP directs associating PDE4D3 to localize around the nucleus. PKA phosphorylation of PDE4D3 at Ser13 enhances the affinity of PDE4D3 for mAKAP, which functions as perinuclear negative-feedback regulation of cAMP signaling in addition to PKA-mediated activation.152 Furthermore, PDE4D3 acts as an adaptor protein of Epac1. Thus, mAKAP constitutes a complex with PKA, PDE4D3, and Epac1 for regulation of cAMP signaling.151 AKAP450, myomegalin, and myeloid translocation gene (MTG), which anchor to the Golgi, the Golgi, and the centrosome, interact with PDE4A, PDE4D3, and PDE4D3, respectively. PDE4 association with AKAPs has also been shown to prevent AKAP-anchored PKA from activation by cAMP at basal levels.153
TAPAS-1 (tryptophan anchoring phosphatidic acid selective-binding domain 1) domain participates to PDE4A1 membrane anchoring through interaction with phosphatidic acid in phospholipid vesicles.154 Membrane-anchored PDE4A1 is subject to Ca2+-stimulated intracellular redistribution depending on phospholipase D–mediated phosphatidic acid generation, which allows crosstalk among cAMP, phospholipase D, and Ca2+ signaling pathways.155
Phosphodiesterase 5
Cellular localization of PDE5 is cytosolic. PDE5A is localized in Z band in cardiac myocytes, suggesting an association of PDE5 with certain proteins.156 However, there is no evidence of direct binding. Sequestration of cGMP by localized cGMP-binding proteins such as PDE5 and PKG might be involved in the spatial regulation of cGMP signaling.157
Phosphodiesterase 6
C termini of rod PDE (PDE6 and PDE6ß) contain a carboxyl-terminal motif for prenylation and carboxyl methylation. PDE6 and PDE6ß, which are farnesylated and geranylgeranylated, respectively, are membrane anchored. The small subunit PDE6
, which is a prenyl-binding protein,158 directly interacts with rod PDE and dissociates the complex from the rod outer segment disc membrane without changing PDE activity.159
Phosphodiesterase 7
PDE7A2 with an N-terminal hydrophobic region is localized to particulate fractions.26 PDE7A1 colocalizes with the RII PKA regulatory subunit in the Golgi–centrosome region of ß-TC3 insulinoma cells.160 N-terminal PKA pseudosubstrate sites in human PDE7A1 bind to PKA catalytic subunits and inhibit kinase activity.26,160 Myeloid translocation gene (MTG) protein also binds to and colocalizes with PDE7A in the Golgi of HuT78 cells.161 PDE7B localization is unknown. Recombinant human PDE7B1 protein with an N-terminal FLAG-tag expressed in COS-7 cells is cytosolic.71
Phosphodiesterase 8
A consensus sequence for myristoylation/palmitoylation motif, MGCAP, is present in human PDE8A1 and PDE8B1. However, subcellular localization of PDE8 proteins is unknown. N-terminal Xpress-tagged human PDE8A1 and PDE8B1 proteins are found in both cytosolic and particulate fractions of COS-7 cells.27
Phosphodiesterase 9
PDE9A1, PDE9A16, and PDE9A17 have a pat7 nuclear localization signal, PLRDRRV. Nuclear localization of recombinant PDE9A1 is determined by the pat7 motif.80
Phosphodiesterase 10
Recombinant proteins of PDE10A1 and PDE10A3 are cytosolic.162 By contrast, endogenous PDE10A2 protein from rat striatum as well as recombinant PDE10A2, which is found in the Golgi apparatus of transfected PC12H cells, is dominant in membrane fractions. By PKA phosphorylation, PDE10A2 alters subcellular localization from Golgi to cytosol.162 cAMP signaling in Golgi and cytosol of neurons is hypothesized to be controlled through alteration of PDE10A subcellular localization by PKA.
Phosphodiesterase 11
Subcellular localization of PDE11A is unknown. N-terminal Xpress-tagged recombinant PDE11A proteins are cytosolic in COS-7 cells.34,88
|
Phenotypes of Genetically Engineered Animals |
|---|
|
TopAbstractIntroductionPDE FamilyGeneral CharacteristicsPDE Variants and Their...Gene Regulation in PDEsEnzymatic Regulation of PDEs...Subcellular Localization of...Phenotypes of Genetically...ConclusionsReferences |
|---|
Phenotypes of genetically engineered animals are summarized in Table 2. In this regard, there is no report on PDE1A, PDE1C, PDE2A, PDE4C, PDE5A, PDE6A-C, PDE7B, PDE8A-B, and PDE9A.
Phosphodiesterase 1
PDE1B-deficient mice163 show increased locomotor activity and deficits in spatial learning.
Phosphodiesterase 3
Female PDE3A-deficient mice164 are infertile because of immature oocytes, demonstrating the involvement of PDE3A in oocyte maturation and fertilization. However, alterations in contraction and relaxation of cardiac and vascular myocytes and platelet aggregation in PDE3A–/– mice have not yet been reported.
PDE3B transgenic mice (ß-cell specific) demonstrate impaired acute insulin response to intravenous glucose loads and reduced insulin secretion in islets in vitro.165 PDE3B plays a crucial role in regulation of cAMP signaling in ß-cell insulin secretion.
Phosphodiesterase 4
Knockout mice for PDE4A (PDE4A–/–), PDE4B (PDE4B–/–), and PDE4D (PDE4D–/–) have been reported.166,167 Although there are only a few reports on PDE4A–/– mice, it is believed that no obvious phenotype exists in cardiac or immune system.
Immune response is altered in PDE4B–/– mice.167,168 PDE4B–/– mice have impaired lipopolysaccharide-stimulated TNF production and are resistant to lipopolysaccharide-induced shock. PDE4B has critical function in lipopolysaccharide signaling. In an endotoxin inhalation–induced lung injury model, recruitment of neutrophils is markedly decreased in PDE4D–/– and PDE4B–/– mice. CD18 expression and chemotaxis response are decreased in PDE4D–/– and PDE4B–/– neutrophils.169 Neutrophil function is regulated by PDE4B and PDE4D.
PDE4D–/– but not PDE4B–/– mice exhibit impaired airway contraction induced by cholinergic stimulation and abolished airway hyperreactivity caused by exposure to allergen, indicating the implication of PDE4D gene in cholinergic airway responsiveness and in development of hyperreactivity.170,171
Progressive cardiomyopathy, accelerated heart failure after myocardial infarction, and cardiac arrhythmias are observed in PDE4D–/– mice.172 PDE4D3 is associated with RyR2/calcium-release-channel complex, which is required for heart muscle excitation/contraction. Depletion of PDE4D3 in RyR2 complex enhances PKA phosphorylation of the complex and affects controlled intracellular Ca2+ release, resulting in cardiac dysfunction and arrhythmia.
In the central nervous system, PDE4D has been reported to be linked to cAMP signaling of 2-adrenoceptor in noradrenergic neurons, which may explain the emetic side effect of PDE4 inhibitors.173
Phosphodiesterase 6
Mutations in genes generating defective PDE6 enzymes (mainly rod PDE6ß) cause high-level cGMP accumulation in photoreceptor cells leading to cell death.174
Phosphodiesterase 7
T-lymphocyte activation has been proposed to be linked to PDE7A activity.175 However, PDE7A knockout mice (PDE7A–/–) have been reported to show normal in vitro and in vivo T-cell functions, indicating that T-cell activation does not require PDE7A activity.176
Phosphodiesterase 10
PDE10A knockout (PDE10A–/–) mice177 show decreased exploratory activity and delayed acquisition of conditioned avoidance behavior. A blunted locomotor response is observed in PDE10A–/– mice following administration of antagonists for the ionotropic N-methyl-D-aspartate receptor that induce locomotor hyperactivity. PDE10A has a particular role in the responsiveness of MSNs to glutamatergic stimulation.
Phosphodiesterase 11
PDE11A knockout mice (PDE11–/–)178 demonstrate impaired sperm function and spermatogenesis, suggesting involvement of PDE11A activity in spermatogenesis. In humans, a protein corresponding to PDE11A3, which is a testis-specific variant, is undetectable in testicular tissue,87 whereas PDE11A4 protein is present in the prostate, where prostatic fluid involved in sperm activity is produced. The effects of PDE11A disruption on prostatic function are unknown, and therefore the physiological role of PDE11A should not be linked simply to testicular functions.
|
Conclusions |
|---|
|
TopAbstractIntroductionPDE FamilyGeneral CharacteristicsPDE Variants and Their...Gene Regulation in PDEsEnzymatic Regulation of PDEs...Subcellular Localization of...Phenotypes of Genetically...ConclusionsReferences |
|---|
A number of splice variants have been identified in each PDE family, as described here. In regard to certain variants of classical PDEs (PDE1 to -6), molecular characteristics, tissue expression patterns, and expression regulation, all of which are indispensable information to figure out PDE functional roles in cells, have to some extent been investigated. By contrast, less information on newly discovered higher-numbered PDE families (PDE7 to -11) is currently available. Lack of clear evidence for the presence of apparent activity in most of the newly discovered PDEs in tissues and cells is the major obstacle to picture a precise and detailed network of intracellular signaling, where these PDE enzymes are involved in regulation of cellular functions.
Functional roles of PDEs have been studied using PDE family–specific inhibitors to demonstrate pharmacological effects of inhibition of each PDE family. However, PDE inhibitors cannot distinguish isoform-specific and variant-specific functions of PDE. Therefore, isoform-specific, highly selective PDE inhibitors, RNA interference, and genetically engineered animals, such as variant-specific knockout animals, seem to be potent and plausible tools to solve the specificity issue. Moreover, comparative studies looking at the whole picture of PDEs would be very important to evaluate the involvement of each PDE in specific cellular function and to understand regulation of cyclic nucleotide signaling. Establishment of a standardized platform for PDE research is necessary to interpret further intriguing observations.
|
Acknowledgments |
|---|
Sources of Funding
The preparation of this article was supported by Tanabe Seiyaku Co Ltd (Osaka, Japan).
Disclosures
None.
|
Footnotes |
|---|
Original received September 11, 2006; revision received December 6, 2006; accepted December 14, 2006.
|
References |
|---|
|
TopAbstractIntroductionPDE FamilyGeneral CharacteristicsPDE Variants and Their...Gene Regulation in PDEsEnzymatic Regulation of PDEs...Subcellular Localization of...Phenotypes of Genetically...ConclusionsReferences |
|---|
1. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006; 58: 488–520.
2. Degerman E, Belfrage P, Manganiello VC. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem. 1997; 272: 6823–6826.
3. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J. 2003; 370: 1–18.[CrossRef][Medline] [Order article via Infotrieve]
4. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol. 2001; 65: 1–52.[Medline] [Order article via Infotrieve]
5. Cote RH. Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. Int J Impot Res. 2004; 16 (suppl 1): S28–S33.[CrossRef][Medline] [Order article via Infotrieve]
6. McConnachie G, Langeberg LK, Scott JD. AKAP signaling complexes: getting to the heart of the matter. Trends Mol Med. 2006; 12: 317–323.[CrossRef][Medline] [Order article via Infotrieve]
7. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994; 22: 4673–4680.
8. Loughney K, Martins TJ, Harris EA, Sadhu K, Hicks JB, Sonnenburg WK, Beavo JA, Ferguson K. Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases. J Biol Chem. 1996; 271: 796–806.
9. Bender AT, Ostenson CL, Wang EH, Beavo JA. Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation. Proc Natl Acad Sci U S A. 2005; 102: 497–502.
10. Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG, Beavo JA. The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci U S A. 2002; 99: 13260–13265.
11. Wechsler J, Choi YH, Krall J, Ahmad F, Manganiello VC, Movsesian MA. Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem. 2002; 277: 38072–38078.
12. Houslay MD. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol. 2001; 69: 249–315.[Medline] [Order article via Infotrieve]
13. Bolger G, Michaeli T, Martins T, St John T, Steiner B, Rodgers L, Riggs M, Wigler M, Ferguson K. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol. 1993; 13: 6558–6571.
14. Beard MB, Olsen AE, Jones RE, Erdogan S, Houslay MD, Bolger GB. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase (PDE4) family form a discrete module via electrostatic interactions. J Biol Chem. 2000; 275: 10349–10358.
15. Sette C, Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem. 1996; 271: 16526–16534.
16. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 1999; 18: 893–903.[CrossRef][Medline] [Order article via Infotrieve]
17. Grange M, Sette C, Cuomo M, Conti M, Lagarde M, Prigent AF, Nemoz G. The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site. J Biol Chem. 2000; 275: 33379–33387.
18. Lim J, Pahlke G, Conti M. Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain. J Biol Chem. 1999; 274: 19677–19685.
19. Richter W, Conti M. Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs). J Biol Chem. 2002; 277: 40212–40221.
20. Liu L, Underwood T, Li H, Pamukcu R, Thompson WJ. Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase. Cell Signal. 2002; 14: 45–51.[CrossRef][Medline] [Order article via Infotrieve]
21. Corbin JD, Turko IV, Beasley A, Francis SH. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem. 2000; 267: 2760–2767.[Medline] [Order article via Infotrieve]
22. Zoraghi R, Bessay EP, Corbin JD, Francis SH. Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem. 2005; 280: 12051–12063.
23. Francis SH, Bessay EP, Kotera J, Grimes KA, Liu L, Thompson WJ, Corbin JD. Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J Biol Chem. 2002; 277: 47581–47587.
24. Muradov KG, Boyd KK, Martinez SE, Beavo JA, Artemyev NO. The GAFa domains of rod cGMP-phosphodiesterase 6 determine the selectivity of the enzyme dimerization. J Biol Chem. 2003; 278: 10594–10601.
25. Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA, Wigler M. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem. 1993; 268: 12925–12932.
26. Han P, Zhu X, Michaeli T. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem. 1997; 272: 16152–16157.
27. Gamanuma M, Yuasa K, Sasaki T, Sakurai N, Kotera J, Omori K. Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans. Cell Signal. 2003; 15: 565–574.[CrossRef][Medline] [Order article via Infotrieve]
28. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 1998; 273: 15559–155564.
29. Guipponi M, Scott HS, Kudoh J, Kawasaki K, Shibuya K, Shintani A, Asakawa S, Chen H, Lalioti MD, Rossier C, Minoshima S, Shimizu N, Antonarakis SE. Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence. Hum Genet. 1998; 103: 386–392.[CrossRef][Medline] [Order article via Infotrieve]
30. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, Omori K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem. 1999; 274: 18438–18445.
31. Fujishige K, Kotera J, Omori K. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem. 1999; 266: 1118–1127.[Medline] [Order article via Infotrieve]
32. Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A, Schultz JE. cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem. 2006; 281: 2841–2846.
33. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology. 2006; 51: 386–396.[CrossRef][Medline] [Order article via Infotrieve]
34. Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, Omori K. Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J Biol Chem. 2000; 275: 31469–31479.
35. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, Phillips SC. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A. 2000; 97: 3702–3707.
36. Hetman JM, Robas N, Baxendale R, Fidock M, Phillips SC, Soderling SH, Beavo JA. Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci U S A. 2000; 97: 12891–12895.
37. Michibata H, Yanaka N, Kanoh Y, Okumura K, Omori K. Human Ca2+/calmodulin-dependent phosphodiesterase PDE1A: novel splice variants, their specific expression, genomic organization, and chromosomal localization. Biochim Biophys Acta. 2001; 1517: 278–287.[Medline] [Order article via Infotrieve]
38. Snyder PB, Florio VA, Ferguson K, Loughney K. Isolation, expression and analysis of splice variants of a human Ca2+/calmodulin-stimulated phosphodiesterase (PDE1A). Cell Signal. 1999; 11: 535–544.[CrossRef][Medline] [Order article via Infotrieve]
39. Fidock M, Miller M, Lanfear J. Isolation and differential tissue distribution of two human cDNAs encoding PDE1 splice variants. Cell Signal. 2002; 14: 53–60.[CrossRef][Medline] [Order article via Infotrieve]
40. Yan C, Bentley JK, Sonnenburg WK, Beavo JA. Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. J Neurosci. 1994; 14: 973–984.[Abstract]
41. Yu J, Frazier ALB, Wolda SL, Florio VA, Martins TJ, Snyder PB, Harris EAS, McCaw KN, Farrell CA, Steiner B, Bentley JK, Beavo JA, Ferguson K, Gelinas R. Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1. Cell Signal. 1997; 9: 519–529.[CrossRef][Medline] [Order article via Infotrieve]
42. Yan C, Zhao A, Bentley JK, Beavo JA. The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue specific manner. J Biol Chem. 1996; 271: 25699–25706.
44. Yan C, Zhao AZ, Bentley JK, Loughney K, Ferguson K, Beavo JA. Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proc Natl Acad Sci U S A. 1995; 92: 9677–9681.
45. Rosman GJ, Martins TJ, Sonnenburg WK, Beavo JA, Ferguson K, Loughney K. Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase. Gene. 1997; 191: 89–95.[CrossRef][Medline] [Order article via Infotrieve]
46. Sadhu K, Hensley K, Florio VA, Wolda SL. Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells. J Histochem Cytochem. 1999; 47: 895–906.
47. Suttorp N, Hippenstiel S, Fuhrmann M, Krull M, Podzuweit T. Role of nitric oxide and phosphodiesterase isoenzyme II for reduction of endothelial hyperpermeability. Am J Physiol. 1996; 270: C778–C785.[Medline] [Order article via Infotrieve]
48. Choi YH, Ekholm D, Krall J, Ahmad F, Degerman E, Manganiello VC, Movsesian MA. Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J. 2001; 353: 41–50.[Medline] [Order article via Infotrieve]
49. Kasuya J, Goko H, Fujita-Yamagichi Y. Multiple Transcripts for the human cardiac form of the cGMP-inhibited cAMP phosphodiesterase. J Biol Chem. 1995; 270: 14305–14312.
50. Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC, Bondy CA. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest. 1995; 95: 1528–1538.[Medline] [Order article via Infotrieve]
51. Miki T, Taira M, Hockman S, Shimada F, Lieman J, Napolitano M, Ward D, Taira M, Makino H, Manganiello VC. Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human cyclic GMP-inhibited cyclic nucleotide phosphodiesterase family. Genomics. 1996; 36: 476–485.[CrossRef][Medline] [Order article via Infotrieve]
52. Engels P, Fichtel K, Lubbert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 1994; 350: 291–295.[CrossRef][Medline] [Order article via Infotrieve]
53. Engels P, Sullivan M, Muller T, Lubbert H. Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett. 1995; 358: 305–310.[CrossRef][Medline] [Order article via Infotrieve]
54. Rena G, Begg F, Ross A, MacKenzie C, McPhee I, Campbell L, Huston E, Sullivan M, Houslay MD. Molecular cloning and characterization of the novel cAMP specific phosphodiesterase, PDE4A10. Mol Pharmacol. 2001; 59: 996–1011.
55. Wallace DA, Johnston LA, Huston E, MacMaster D, Houslay TM, Cheung YF, Campbell L, Millen JE, Smith RA, Gall I, Knowles RG, Sullivan M, Houslay MD. Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene. Mol Pharmacol. 2005; 67: 1920–1934.
56. D’Sa C, Eisch AJ, Bolger GB, Duman RS. Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur J Neurosci. 2005; 22: 1463–1475.[CrossRef][Medline] [Order article via Infotrieve]
57. Shepherd M, McSorley T, Olsen AE, Johnston LA, Thomson NC, Baillie GS, Houslay MD, Bolger GB. Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. Biochem J. 2003; 370: 429–438.[CrossRef][Medline] [Order article via Infotrieve]
58. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol. 1999; 56: 170–174.
59. Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA, Aguiar RC. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood. 2005; 105: 308–316.
61. Bolger GB, Erdogan S, Jones RE, Loughney K, Scotland G, Hoffmann R, Wilkinson I, Farrell C, Houslay MD. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J. 1997; 328: 539–548.[Medline] [Order article via Infotrieve]
62. Wang D, Deng C, Bugaj-Gaweda B, Kwan M, Gunwaldsen C, Leonard C, Xin X, Hu Y, Unterbeck A, De Vivo M. Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7. Cell Signal. 2003; 15: 883–891.[CrossRef][Medline] [Order article via Infotrieve]
63. Beard MB, O’Connell JC, Bolger GB, Houslay MD. The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains. FEBS Lett. 1999; 460: 173–177.[CrossRef][Medline] [Order article via Infotrieve]
64. Barnes AP, Livera G, Huang P, Sun C, O’Neal WK, Conti M, Stutts MJ, Milgram SL. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J Biol Chem. 2005; 280: 7997–8003.
65. Richter W, Jin SL, Conti M. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem J. 2005; 388: 803–811.[CrossRef][Medline] [Order article via Infotrieve]
66. Yanaka N, Kotera J, Ohtsuka A, Akatsuka H, Imai Y, Michibata H, Fujishige K, Kawai E, Takebayashi S, Okumura K, Omori K. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem. 1998; 255: 391–399.[Medline] [Order article via Infotrieve]
67. Kotera J, Fujishige K, Imai Y, Kawai E, Michibata H, Akatsuka H, Yanaka N, Omori K. Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. Eur J Biochem. 1999; 262: 866–873.[Medline] [Order article via Infotrieve]
68. Lin CS, Lau A, Tu R, Lue TF. Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun. 2000; 268: 628–635.[CrossRef][Medline] [Order article via Infotrieve]
69. Glavas NA, Ostenson C, Schaefer JB, Vasta V, Beavo JA. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci U S A. 2001; 98: 6319–6324.
70. Bloom TJ, Beavo JA. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci U S A. 1996; 93: 14188–14192.
71. Sasaki T, Kotera J, Yuasa K, Omori K. Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun. 2000; 271: 575–583.[CrossRef][Medline] [Order article via Infotrieve]
72. Sasaki T, Kotera J, Omori K. Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem J. 2002; 361: 211–220.[CrossRef][Medline] [Order article via Infotrieve]
73. Reyes-Irisarri E, Perez-Torres S, Mengod G. Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience. 2005; 132: 1173–1185.[CrossRef][Medline] [Order article via Infotrieve]
74. Hetman JM, Soderling SH, Glavas NA, Beavo JA. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc Natl Acad Sci U S A. 2000; 97: 472–476.
75. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun. 1998; 246: 570–577.[CrossRef][Medline] [Order article via Infotrieve]
76. Wang P, Wu P, Egan RW, Billah MM. Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution. Gene. 2001; 280: 183–194.[CrossRef][Medline] [Order article via Infotrieve]
77. Kobayashi T, Gamanuma M, Sasaki T, Yamashita Y, Yuasa K, Kotera J, Omori K. Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain. Gene. 2003; 319: 21–31.[CrossRef][Medline] [Order article via Infotrieve]
78. Hayashi M, Matsushima K, Ohashi H, Tsunoda H, Murase S, Kawarada Y, Tanaka T. Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun. 1998; 250: 751–756.[CrossRef][Medline] [Order article via Infotrieve]
79. Rentero C, Monfort A, Puigdomenech P. Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. Biochem Biophys Res Commun. 2003; 301: 686–692.[CrossRef][Medline] [Order article via Infotrieve]
80. Wang P, Wu P, Egan RW, Billah MM. Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. Gene. 2003; 314: 15–27.[CrossRef][Medline] [Order article via Infotrieve]
81. Fujishige K, Kotera J, Yuasa K, Omori K. The human phosphodiesterase PDE10A gene genomic organization and evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem. 2000; 267: 5943–5951.[Medline] [Order article via Infotrieve]
82. Kotera J, Fujishige K, Yuasa K, Omori K. Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP. Biochem Biophys Res Commun. 1999; 261: 551–557.[CrossRef][Medline] [Order article via Infotrieve]
83. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD, Wylie PG, Menniti FS. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003; 985: 113–126.[CrossRef][Medline] [Order article via Infotrieve]
84. Soderling SH, Bayuga SJ, Beavo JA. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem. 1998; 273: 15553–15558.
85. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, Stephenson DT. Immunohistochemical localization of phosphodiesterase 10A (PDE10A) in multiple mammalian species. J Histochem Cytochem. 2006; 54: 1205–1213.
86. Yuasa K, Kanoh Y, Okumura K, Omori K. Genomic organization of the human phosphodiesterase PDE11A gene. Evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem. 2001; 268: 168–178.[Medline] [Order article via Infotrieve]
87. Loughney K, Taylor J, Florio VA. 3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int J Impot Res. 2005; 17: 320–325.[CrossRef][Medline] [Order article via Infotrieve]
88. Yuasa K, Ohgaru T, Asahina M, Omori K. Identification of rat cyclic nucleotide phosphodiesterase 11A (PDE11A): comparison of rat and human PDE11A splicing variants. Eur J Biochem. 2001; 268: 4440–4448.[Medline] [Order article via Infotrieve]
89. Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC, Yan C. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation. 2001; 104: 2338–2343.
90. Spence S, Rena G, Sullivan M, Erdogan S, Houslay MD. Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase. Biochem J. 1997; 321: 157–163.[Medline] [Order article via Infotrieve]
91. Bender AT, Ostenson CL, Giordano D, Beavo JA. Differentiation of human monocytes in vitro with granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor produces distinct changes in cGMP phosphodiesterase expression. Cell Signal. 2004; 16: 365–374.[CrossRef][Medline] [Order article via Infotrieve]
92. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hansen K, Krebs EG, Beavo JA. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest. 1997; 100: 2611–2621.[Medline] [Order article via Infotrieve]
93. Kostic MM, Erdogan S, Rena G, Borchert G, Hoch B, Bartel S, Scotland G, Huston E, Houslay MD, Krause EG. Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. J Mol Cell Cardiol. 1997; 29: 3135–3146.[CrossRef][Medline] [Order article via Infotrieve]
94. Viguerie N, Clement K, Barbe P, Courtine M, Benis A, Larrouy D, Hanczar B, Pelloux V, Poitou C, Khalfallah Y, Barsh GS, Thalamas C, Zucker JD, Langin D. In vivo epinephrine-mediated regulation of gene expression in human skeletal muscle. J Clin Endocrinol Metab. 2004; 89: 2000–2014.
95. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Burger A, Hatzelmann A, Tenor H, Schudt C, Krull M, Schutte H, Hippenstiel S, Suttorp N. Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood. 2005; 105: 3569–3576.
96. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA, Zhao A, Sadoshima J, Blaxall BC, Berk BC, Yan C. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation. 2005; 111: 2469–2476.
97. Ding B, Abe J, Wei H, Xu H, Che W, Aizawa T, Liu W, Molina CA, Sadoshima J, Blaxall BC, Berk BC, Yan C. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A. 2005; 102: 14771–14776.
98. Ogura T, Osawa H, Tang Y, Onuma H, Ochi M, Nishimiya T, Kubota N, Terauchi Y, Kadowaki T, Makino H. Reduction of phosphodiesterase 3B gene expression in peroxisome proliferator-activated receptor gamma (+/-) mice independent of adipocyte size. FEBS Lett. 2003; 542: 65–68.[CrossRef][Medline] [Order article via Infotrieve]
99. Niiya T, Osawa H, Onuma H, Suzuki Y, Taira M, Yamada K, Makino H. Activation of mouse phosphodiesterase 3B gene promoter by adipocyte differentiation in 3T3–L1 cells. FEBS Lett. 2001; 505: 136–140.[CrossRef][Medline] [Order article via Infotrieve]
100. Rahn Landstrom T, Mei J, Karlsson M, Manganiello V, Degerman E. Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3–L1 adipocytes induced by tumour necrosis factor and cAMP. Biochem J. 2000; 346: 337–343.[CrossRef][Medline]
[Order article via Infotrieve]
101. Mei J, Holst LS, Landstrom TR, Holm C, Brindley D, Manganiello V, Degerman E. C2-ceramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3–L1 adipocytes. Diabetes. 2002; 51: 631–637.
102. Conti AC, Blendy JA. Regulation of antidepressant activity by cAMP response element binding proteins. Mol Neurobiol. 2004; 30: 143–155.[CrossRef][Medline] [Order article via Infotrieve]
103. Torphy TJ, Zhou HL, Foley JJ, Sarau HM, Manning CD, Barnette MS. Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists. J Biol Chem. 1995; 270: 23598–23604.
104. Ma D, Wu P, Egan RW, Billah MM, Wang P. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol. 1999; 55: 50–57.
105. Shepherd MC, Baillie GS, Stirling DI, Houslay MD. Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol. 2004; 142: 339–351.[CrossRef][Medline] [Order article via Infotrieve]
106. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, Heeke GV. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol. 2004; 287: L332–L343.
107. Vicini E, Conti M. Characterization of an intronic promoter of a cyclic adenosine 3',5'-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol Endocrinol. 1997; 11: 839–850.
108. Le Jeune IR, Shepherd M, Van Heeke G, Houslay MD, Hall IP. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J Biol Chem. 2002; 277: 35980–35989.
109. Lin CS, Chow S, Lau A, Tu R, Lue TF. Identification and regulation of human PDE5A gene promoter. Biochem Biophys Res Commun. 2001; 280: 684–692.[CrossRef][Medline] [Order article via Infotrieve]
110. Lin CS, Chow S, Lau A, Tu R, Lue TF. Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. Biochem Biophys Res Commun. 2001; 280: 693–699.[CrossRef][Medline] [Order article via Infotrieve]
111. Kotera J, Fujishige K, Omori K. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem. 2000; 48: 685–693.
112. Vernet D, Magee T, Qian A, Nolazco G, Rajfer J, Gonzalez-Cadavid N. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med. 2006; 3: 84–94.[CrossRef][Medline] [Order article via Infotrieve]
113. Pittler SJ, Zhang Y, Chen S, Mears AJ, Zack DJ, Ren Z, Swain PK, Yao S, Swaroop A, White JB. Functional analysis of the rod photoreceptor cGMP phosphodiesterase alpha-subunit gene promoter: Nrl and Crx are required for full transcriptional activity. J Biol Chem. 2004; 279: 19800–19807.
114. Lerner LE, Peng GH, Gribanova YE, Chen S, Farber DB. Sp4 is expressed in retinal neurons, activates transcription of photoreceptor-specific genes, and synergizes with Crx. J Biol Chem. 2005; 280: 20642–20650.
115. Torras-Llort M, Azorin F. Functional characterization of the human phosphodiesterase 7A1 promoter. Biochem J. 2003; 373: 835–843.[CrossRef][Medline] [Order article via Infotrieve]
116. Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, Lerner A. PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signal. 2002; 14: 277–284.[CrossRef][Medline] [Order article via Infotrieve]
117. Sasaki T, Kotera J, Omori K. Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. J Neurochem. 2004; 89: 474–483.[Medline] [Order article via Infotrieve]
118. Florio VA, Sonnenburg WK, Johnson R, Kwak KS, Jensen GS, Walsh KA, Beavo JA. Phosphorylation of the 61-kDa calmodulin-stimulated cyclic nucleotide phosphodiesterase at serine 120 reduces its affinity for calmodulin. Biochemistry. 1994; 33: 8948–8954.[CrossRef][Medline] [Order article via Infotrieve]
119. Hashimoto Y, Sharma RK, Soderling TR. Regulation of Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase by the autophosphorylated form of Ca2+/calmodulin-dependent protein kinase II. J Biol Chem. 1989; 264: 10884–10887.
120. Ang KL, Antoni FA. Reciprocal regulation of calcium dependent and calcium independent cyclic AMP hydrolysis by protein phosphorylation. J Neurochem. 2002; 81: 422–433.[CrossRef][Medline] [Order article via Infotrieve]
121. Geoffroy V, Fouque F, Nivet V, Clot JP, Lugnier C, Desbuquois B, Benelli C. Activation of a cGMP-stimulated cAMP phosphodiesterase by protein kinase C in a liver Golgi-endosomal fraction. Eur J Biochem. 1999; 259: 892–900.[Medline] [Order article via Infotrieve]
122. Bentley JK. Immunoprecipitation of PDE2 phosphorylated and inactivated by an associated protein kinase. Methods Mol Biol. 2005; 307: 211–223.[Medline] [Order article via Infotrieve]
123. Pozuelo Rubio M, Campbell DG, Morrice NA, Mackintosh C. Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. Biochem J. 2005; 392: 163–172.[CrossRef][Medline] [Order article via Infotrieve]
124. Rahn T, Ronnstrand L, Leroy MJ, Wernstedt C, Tornqvist H, Manganiello VC, Belfrage P, Degerman E. Identification of the site in the cGMP-inhibited phosphodiesterase phosphorylated in adipocytes in response to insulin and isoproterenol. J Biol Chem. 1996; 271: 11575–11580.
125. Rascon A, Degerman E, Taira M, Meacci E, Smith CJ, Manganiello V, Belfrage P, Tornqvist H. Identification of the phosphorylation site in vitro for cAMP-dependent protein kinase on the rat adipocyte cGMP-inhibited cAMP phosphodiesterase. J Biol Chem. 1994; 269: 11962–11966.
126. Kitamura T, Kitamura Y, Kuroda S, Hino Y, Ando M, Kotani K, Konishi H, Matsuzaki H, Kikkawa U, Ogawa W, Kasuga M. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol Cell Biol. 1999; 19: 6286–6296.
127. Onuma H, Osawa H, Yamada K, Ogura T, Tanabe F, Granner DK, Makino H. Identification of the insulin-regulated interaction of phosphodiesterase 3B with 14-3-3 ß protein. Diabetes. 2002; 51: 3362–3367.
128. Laliberte F, Liu S, Gorseth E, Bobechko B, Bartlett A, Lario P, Gresser MJ, Huang Z. In vitro PKA phosphorylation-mediated human PDE4A4 activation. FEBS Lett. 2002; 512: 205–208.[CrossRef][Medline] [Order article via Infotrieve]
129. Hoffmann R, Wilkinson IR, McCallum JF, Engels P, Houslay MD. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem J. 1998; 333: 139–149.[Medline] [Order article via Infotrieve]
130. MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, Houslay, MD. ERK2 MAP kinase binding, phosphorylation and regulation of PDE4D cAMP specific phosphodiesterases: the involvement of C-terminal docking sites and N-terminal UCR regions. J Biol Chem. 2000; 275: 16609–16617.
131. Nemoz G, Sette C, Conti M. Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. Mol Pharmacol. 1997; 51: 242–249.
132. Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS, Houslay MD. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem. 2003; 278: 33351–33363.
133. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, Chubb JE, Huston E, Baillie GS, Thomson PA, Hill EV, Brandon NJ, Rain JC, Camargo LM, Whiting PJ, Houslay MD, Blackwood DH, Muir WJ, Porteous DJ. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science. 2005; 310: 1187–1191.
134. O’Connell JC, McCallum JF, McPhee I, Wakefield J, Houslay ES, Wishart W, Bolger G, Frame M, Houslay MD. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). Biochem J. 1996; 318: 255–261.[Medline] [Order article via Infotrieve]
135. McPhee I, Yarwood SJ, Scotland G, Huston E, Beard MB, Ross AH, Houslay ES, Houslay MD. Association with the src family tyrosyl kinase lyn triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B: consequences for rolipram inhibition. J Biol Chem. 1999; 274: 11796–11810.
136. Lochhead A, Nekrasova E, Arshavsky VY, Pyne NJ. The regulation of the cGMP-binding cGMP phosphodiesterase by proteins that are immunologically related to the g subunit of the photoreceptor cGMP phosphodiesterase. J Biol Chem. 1997; 272: 18397–18403.
137. Granovsky AE, Natochin M, McEntaffer RL, Haik TL, Francis SH, Corbin JD, Artemyev NO. Probing domain functions of chimeric PDE6'/PDE5 cGMP-phosphodiesterase. J Biol Chem. 1998; 273: 24485–24490.
138. Wu P, Wang P. Per-Arnt-Sim domain-dependent association of cAMP-phosphodiesterase 8A1 with IB proteins. Proc Natl Acad Sci U S A. 2004; 101: 17634–17639.
139. Nagel DJ, Aizawa T, Jeon KI, Liu W, Mohan A, Wei H, Miano JM, Florio VA, Gao P, Korshunov VA, Berk BC, Yan C. Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res. 2006; 98: 777–784.
140. Yang Q, Paskind M, Bolger G, Thompson WJ, Repaske DR, Cutler LS, Epstein PM. A novel cyclic GMP stimulated phosphodiesterase from rat brain. Biochem Biophys Res Commun. 1994; 205: 1850–1858.[CrossRef][Medline] [Order article via Infotrieve]
141. Noyama K, Maekawa S. Localization of cyclic nucleotide phosphodiesterase 2 in the brain-derived Triton-insoluble low-density fraction (raft). Neurosci Res. 2003; 45: 141–148.[CrossRef][Medline] [Order article via Infotrieve]
142. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res. 2006; 98: 226–234.
143. Shakur Y, Takeda K, Kenan Y, Yu ZX, Rena G, Brandt D, Houslay MD, Degerman E, Ferrans VJ, Manganiello VC. Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J Biol Chem. 2000; 275: 38749–38761.
144. Nilsson R, Ahmad F, Sward K, Andersson U, Weston M, Manganiello V, Degerman E. Plasma membrane cyclic nucleotide phosphodiesterase 3B (PDE3B) is associated with caveolae in primary adipocytes. Cell Signal. 2006; 18: 1713–1721.[CrossRef][Medline] [Order article via Infotrieve]
145. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, Miller WE, McLean AJ, Conti M, Houslay MD, Lefkowitz RJ. Targeting of cyclic AMP degradation to ß2-adrenergic receptors by ß-arrestins. Science. 2002; 298: 834–836.
146. Bolger GB, Baillie GS, Li X, Lynch MJ, Herzyk P, Mohamed A, Mitchell LH, McCahill A, Hundsrucker C, Klussmann E, Adams DR, Houslay MD. Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, ß-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Biochem J. 2006; 398: 23–36.[CrossRef][Medline] [Order article via Infotrieve]
147. Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, van Heeke G, Houslay MD. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with ß arrestin to control the protein kinase A/AKAP79-mediated switching of the ß2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem. 2005; 280: 33178–33189.
148. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, Houslay MD. ß-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates ß-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci U S A. 2003; 100: 940–945.
149. Houslay MD, Baillie GS. Beta-Arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of ß2-adrenoceptor signalling to activation of ERK. Biochem Soc Trans. 2005; 33: 1333–1336.[CrossRef][Medline] [Order article via Infotrieve]
150. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A, Mustelin T, Zaccolo M, Houslay M, Tasken K. TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol. 2004; 173: 4847–4858.
151. Dodge-Kafka KL, Soughayer J, Pare GC, Carlisle Michel JJ, Langeberg LK, Kapiloff MS, Scott JD. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature. 2005; 437: 574–578.[CrossRef][Medline] [Order article via Infotrieve]
152. Carlisle Michel JJ, Dodge KL, Wong W, Mayer NC, Langeberg LK, Scott JD. PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. Biochem J. 2004; 381: 587–592.[CrossRef][Medline] [Order article via Infotrieve]
153. McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, van Heeke G, Houslay MD. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal. 2005; 17: 1158–1173.[CrossRef][Medline] [Order article via Infotrieve]
154. Baillie GS, Huston E, Scotland G, Hodgkin M, Gall I, Peden AH, MacKenzie C, Houslay ES, Currie R, Pettitt TR, Walmsley AR, Wakelam MJ, Warwicker J, Houslay MD. TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid. J Biol Chem. 2002; 277: 28298–28309.
155. Huston E, Gall I, Houslay TM, Houslay MD. Helix-1 of the cAMP-specific phosphodiesterase PDE4A1 regulates its phospholipase-D-dependent redistribution in response to release of Ca2+. J Cell Sci. 2006; 119: 3799–37810.
156. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, Paolocci N, Tomaselli GF, Hare JM, Kass DA. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. 2001; 15: 1718–1726.
157. Corbin JD, Kotera J, Gopal VK, Cote RH, Francis SH. Regulation of cyclic nucleotide levels by sequestration. In: Bradshaw R, Dennis E, eds. Handbook of Cell Signaling. San Diego, Calif: Academic Press; 2003: 465–470.
158. Zhang H, Liu XH, Zhang K, Chen CK, Frederick JM, Prestwich GD, Baehr W. Photoreceptor cGMP phosphodiesterase delta subunit (PDEdelta) functions as a prenyl-binding protein. J Biol Chem. 2004; 279: 407–413.
159. Cook TA, Ghomashchi F, Gelb MH, Florio SK, Beavo JA. Binding of the delta subunit to rod phosphodiesterase catalytic subunits requires methylated, prenylated C-termini of the catalytic subunits. Biochemistry. 2000; 39: 13516–13523.[CrossRef][Medline] [Order article via Infotrieve]
160. Han P, Sonati P, Rubin C, Michaeli T. PDE7A1, a cAMP-specific phosphodiesterase, inhibits cAMP-dependent protein kinase by a direct interaction with C. J Biol Chem. 2006; 281: 15050–15057.
161. Asirvatham AL, Galligan SG, Schillace RV, Davey MP, Vasta V, Beavo JA, Carr DW. A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. J Immunol. 2004; 173: 4806–4814.
162. Kotera J, Sasaki T, Kobayashi T, Fujishige K, Yamashita Y, Omori K. Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation. J Biol Chem. 2004; 279: 4366–4375.
163. Reed TM, Repaske DR, Snyder GL, Greengard P, Vorhees CV. Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J Neurosci. 2002; 22: 5188–5197.
164. Masciarelli S, Horner K, Liu C, Park SH, Hinckley M, Hockman S, Nedachi T, Jin C, Conti M, Manganiello V. Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Invest. 2004; 114: 196–205.[CrossRef][Medline] [Order article via Infotrieve]
165. Harndahl L, Wierup N, Enerback S, Mulder H, Manganiello VC, Sundler F, Degerman E, Ahren B, Holst LS. ß-Cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology. J Biol Chem. 2004; 279: 15214–15222.
166. Jin SL, Richard FJ, Kuo WP, D’Ercole AJ, Conti M. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci U S A. 1999; 96: 11998–12003.
167. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A. 2002; 99: 7628–7633.
168. Jin SL, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol. 2005; 175: 1523–1531.
169. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, Jin SL, Conti M. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol. 2004; 173: 7531–7538.
170. Hansen G, Jin S, Umetsu DT, Conti M. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci U S A. 2000; 97: 6751–6756.
171. Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, Conti M. PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J. 2003; 17: 1831–1841.
172. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, Marks AR. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell. 2005; 123: 25–35.[CrossRef][Medline] [Order article via Infotrieve]
173. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F, Liu S, Huang Z, Conti M, Chan CC. Deletion of phosphodiesterase 4D in mice shortens 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002; 110: 1045–1052.[CrossRef][Medline]
[Order article via Infotrieve]
174. Bowes C, Li T, Danciger M, Baxter LC, Applebury ML, Farber DB. Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase. Nature. 1990; 347: 677–680.[CrossRef][Medline] [Order article via Infotrieve]
175. Li L, Yee C, Beavo JA. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science. 1999; 283: 848–851.
176. Yang G, McIntyre KW, Townsend RM, Shen HH, Pitts WJ, Dodd JH, Nadler SG, McKinnon M, Watson AJ. Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol. 2003; 171: 6414–64120.
177. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, Schmidt CJ. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology. 2006; 51: 374–385.[CrossRef][Medline] [Order article via Infotrieve]
178. Wayman C, Phillips S, Lunny C, Webb T, Fawcett L, Baxendale R, Burgess G. Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int J Impot Res. 2005; 17: 216–223.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  D. Larhammar, K. Nordstrom, and T. A. Larsson Evolution of vertebrate rod and cone phototransduction genes Phil Trans R Soc B, October 12, 2009; 364(1531): 2867 - 2880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. de Frutos, C. H. Nitta, E. Caldwell, J. Friedman, and L. V. Gonzalez Bosc Regulation of soluble guanylyl cyclase-{alpha}1 expression in chronic hypoxia-induced pulmonary hypertension: role of NFATc3 and HuR Am J Physiol Lung Cell Mol Physiol, September 1, 2009; 297(3): L475 - L486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kitazawa, S. Semba, Y. H. Huh, K. Kitazawa, and M. Eto Nitric oxide-induced biphasic mechanism of vascular relaxation via dephosphorylation of CPI-17 and MYPT1 J. Physiol., July 15, 2009; 587(14): 3587 - 3603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Margulies, D. P. Bednarik, and D. L. Dries Genomics, transcriptional profiling, and heart failure. J. Am. Coll. Cardiol., May 12, 2009; 53(19): 1752 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Xia, R. Huang, V. Guo, N. Southall, M.-H. Cho, J. Inglese, C. P. Austin, and M. Nirenberg Identification of compounds that potentiate CREB signaling as possible enhancers of long-term memory PNAS, February 17, 2009; 106(7): 2412 - 2417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pokreisz, S. Vandenwijngaert, V. Bito, A. Van den Bergh, I. Lenaerts, C. Busch, G. Marsboom, O. Gheysens, P. Vermeersch, L. Biesmans, et al. Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice Circulation, January 27, 2009; 119(3): 408 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tradtrantip, B. Yangthara, P. Padmawar, C. Morrison, and A. S. Verkman Thiophenecarboxylate Suppressor of Cyclic Nucleotides Discovered in a Small-Molecule Screen Blocks Toxin-Induced Intestinal Fluid Secretion Mol. Pharmacol., January 1, 2009; 75(1): 134 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-C. Chao and K. L. Hamilton Genistein stimulates electrogenic Cl- secretion via phosphodiesterase modulation in the mouse jejunum Am J Physiol Cell Physiol, January 1, 2009; 297(3): C688 - C698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Di Luigi, C. Baldari, P. Sgro, G. P. Emerenziani, M. C. Gallotta, S. Bianchini, F. Romanelli, F. Pigozzi, A. Lenzi, and L. Guidetti The Type 5 Phosphodiesterase Inhibitor Tadalafil Influences Salivary Cortisol, Testosterone, and Dehydroepiandrosterone Sulphate Responses to Maximal Exercise in Healthy Men J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3510 - 3514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Serezani, M. N. Ballinger, D. M. Aronoff, and M. Peters-Golden Cyclic AMP: Master Regulator of Innate Immune Cell Function Am. J. Respir. Cell Mol. Biol., August 1, 2008; 39(2): 127 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Handa, E. Mizohata, S. Kishishita, M. Toyama, S. Morita, T. Uchikubo-Kamo, R. Akasaka, K. Omori, J. Kotera, T. Terada, et al. Crystal Structure of the GAF-B Domain from Human Phosphodiesterase 10A Complexed with Its Ligand, cAMP J. Biol. Chem., July 11, 2008; 283(28): 19657 - 19664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Eur. Respir. J., July 1, 2008; 32(1): 198 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. Kots, B.-K. Choi, M. E. Estrella-Jimenez, C. A. Warren, S. R. Gilbertson, R. L. Guerrant, and F. Murad From the Cover: Pyridopyrimidine derivatives as inhibitors of cyclic nucleotide synthesis: Application for treatment of diarrhea PNAS, June 17, 2008; 105(24): 8440 - 8445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice FASEB J, June 1, 2008; 22(6): 1849 - 1860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dov, E. Abramovitch, N. Warwar, and R. Nesher Diminished Phosphodiesterase-8B Potentiates Biphasic Insulin Response to Glucose Endocrinology, February 1, 2008; 149(2): 741 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Illi, C. D. Russo, C. Colussi, J. Rosati, M. Pallaoro, F. Spallotta, D. Rotili, S. Valente, G. Ragone, F. Martelli, et al. Nitric Oxide Modulates Chromatin Folding in Human Endothelial Cells via Protein Phosphatase 2A Activation and Class II Histone Deacetylases Nuclear Shuttling Circ. Res., January 4, 2008; 102(1): 51 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, M. Ye, H. Robinson, S. H. Francis, and H. Ke Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and Sildenafil Mol. Pharmacol., January 1, 2008; 73(1): 104 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Kass, H. C. Champion, and J. A. Beavo Phosphodiesterase Type 5: Expanding Roles in Cardiovascular Regulation Circ. Res., November 26, 2007; 101(11): 1084 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Funaki, R. R. Hodges, and D. A. Dartt Role of cAMP inhibition of p44/p42 mitogen-activated protein kinase in potentiation of protein secretion in rat lacrimal gland Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1551 - C1560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Schweda, U. Friis, C. Wagner, O. Skott, and A. Kurtz Renin Release Physiology, October 1, 2007; 22(5): 310 - 319. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||